17.92
Travere Therapeutics Inc (TVTX) 最新ニュース
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 - Bluefield Daily Telegraph
Is Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey
10 Best Small-Cap Stocks to Buy Before They Explode - Insider Monkey
Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights - Yahoo Finance
When (TVTX) Moves Investors should Listen - news.stocktradersdaily.com
Travere seeks FDA approval for potential FSGS treatment By Investing.com - Investing.com Australia
Travere rises on co's marketing application for kidney disease drug - TradingView
Travere seeks FDA approval for potential FSGS treatment - Investing.com India
Travere Therapeutics Submits sNDA To FDA For Approval Of Filspari (Sparsentan) For The Treatment Of FSGS - Marketscreener.com
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS - The Manila Times
Travere Therapeutics Submits sNDA for FILSPARI as Potential First FDA-Approved Treatment for FSGS - Nasdaq
Breakthrough: First-Ever FSGS Treatment Could Get FDA Green LightFILSPARI Shows Superior Results - StockTitan
High Growth Tech Stocks In The US With Promising Potential - Simply Wall St
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
US Bancorp DE Has $554,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Travere Therapeutics Expands Team with 77,200 Shares in Strategic Equity Grants - Stock Titan
Focal Segmental Glomerulosclerosis Treatment Market Size - openPR
Is Eli Lilly Stock a Buy? - The Globe and Mail
Why Travere Therapeutics Inc. (TVTX) Went Up On Tuesday? - MSN
What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings - GuruFocus.com
Travere Therapeutics: Tricky Outlook Gives Me Pause For ThoughtDowngrade - Seeking Alpha
When the Price of (TVTX) Talks, People Listen - Stock Traders Daily
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $44.00 - Defense World
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
20,749 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Ieq Capital LLC - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $35.00 at Citigroup - MarketBeat
Wedbush Lowers Earnings Estimates for Travere Therapeutics - Defense World
Can Ligand's Triple FDA Wins Offset Its $31M Q4 Loss? Revenue Jumps 52% - StockTitan
Q1 EPS Estimate for Travere Therapeutics Lowered by Analyst - MarketBeat
Impax Asset Management Group plc Purchases New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Mirum Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Travere Therapeutics' (TVTX) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Analyst Expectations For Travere Therapeutics's Future - Benzinga
Travere Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Citi raises Travere Therapeutics price target to $35, maintains buy By Investing.com - Investing.com Canada
Citi raises Travere Therapeutics price target to $35, maintains buy - Investing.com India
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug - MSN
Travere Therapeutics, Inc. (TVTX): the Best Performing Pharma Stock So Far in 2025 - Insider Monkey
Travere Therapeutics price target raised to $30 from $24 at TD Cowen - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Travere Therapeutics’ Earnings Call Reveals Growth and Challenges - TipRanks
US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 12:07 pm EST - Marketscreener.com
Travere Therapeutics, Inc. SEC 10-K Report - TradingView
Travere therapeutics chief medical officer sells $60k in stock - MSN
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... - Yahoo Finance
Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... By GuruFocus - Investing.com Canada
Travere Therapeutics Posts Strong 2024 Financial Results - TipRanks
Earnings call transcript: Travere Therapeutics Q4 2024 sees earnings beat but stock drops - Investing.com
大文字化:
|
ボリューム (24 時間):